Pharmacokinetic evaluation of idebenone

Bibliography

• Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010;99:246-55
   PubMed Web of Science ®Google Scholar
• Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ. Therapeutic use of coenzyme Q(10) and coenzyme Q(10)-related compounds and formulations. Expert Opin Investig Drugs 2010;19:535-54
   PubMed Web of Science ®Google Scholar
• Durr A, Cossee M, Agid Y, Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996;335:1169-75
   PubMed Web of Science ®Google Scholar
• Campuzano V, Montermini L, Molto MD, Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-7
   PubMed Web of Science ®Google Scholar
• Epplen C, Epplen JT, Frank G, Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet 1997;99:834-6
   PubMed Web of Science ®Google Scholar
• Cossee M, Schmitt M, Campuzano V, Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci USA 1997;94:7452-7
   PubMed Web of Science ®Google Scholar
• Delatycki MB, Williamson R, Forrest SM. Friedreich ataxia: an overview. J Med Genet 2000;37:1-8
   PubMed Web of Science ®Google Scholar
• Schulz JB, Boesch S, Burk K, Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 2009;5:222-34
   PubMed Web of Science ®Google Scholar
• Rotig A, Sidi D, Munnich A, Rustin P. Molecular insights into Friedreich's ataxia and antioxidant-based therapies. Trends Mol Med 2002;8:221-4
   PubMed Web of Science ®Google Scholar
• Buyse G, Mertens L, Di Salvo G, Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 2003;60:1679-81
   PubMed Web of Science ®Google Scholar
• Hausse AO, Aggoun Y, Bonnet D, Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002;87:346-9
   PubMed Web of Science ®Google Scholar
• Meier T, Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol 2009;256(Suppl 1):25-30
   PubMedGoogle Scholar
• Schols L, Vorgerd M, Schillings M, Idebenone in patients with Friedreich ataxia. Neurosci Lett 2001;306:169-72
   PubMed Web of Science ®Google Scholar
• Arnold P, Boulat O, Maire R, Kuntzer T. Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone. Schweiz Arch Neurol Psychiatr 2006;157:169-76
   Google Scholar
• Pineda M, Arpa J, Montero R, Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 2008;12:470-5
   PubMed Web of Science ®Google Scholar
• Ribai P, Pousset F, Tanguy ML, Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 2007;4:558-64
   Google Scholar
• Artuch R, Aracil A, Mas A, Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 2002;33:190-3
   PubMed Web of Science ®Google Scholar
• Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999;354:477-9
   PubMed Web of Science ®Google Scholar
• Schulz JB, Dehmer T, Schols L, Oxidative stress in patients with Friedreich ataxia. Neurology 2000;55:1719-21
   PubMed Web of Science ®Google Scholar
• Mariotti C, Solari A, Torta D, Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003;60:1676-9
   PubMed Web of Science ®Google Scholar
• Rustin P, Rotig A, Munnich A, Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 2002;36:467-9
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Sumner CJ, Penzak SR, Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 2007;64:803-8
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007;6:878-86
   PubMed Web of Science ®Google Scholar
• Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 2010;67:941-7
   PubMed Web of Science ®Google Scholar
• Santhera's MICONOS Trial with Catena®/Sovrima® in Friedreich's Ataxia Misses Primary Endpoint; 2010. Available from: http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=201005&newsid=1417424&newslang=en [Last accessed 22 September 2010]
   Google Scholar
• Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci 2008;1142:133-58
   PubMed Web of Science ®Google Scholar
• Ihara Y, Namba R, Kuroda S, Mitochondrial encephalopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 1989;90:263-71
   PubMed Web of Science ®Google Scholar
• Ikejiri Y, Mori E, Ishii K, Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47:583-5
   PubMed Web of Science ®Google Scholar
• Napolitano A, Salvetti S, Vista M, Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 2000;21:S981-2
   PubMed Web of Science ®Google Scholar
• Study of idebenone in the treatment of mitochondrial encephalopathy lactic acidosis & stroke-like episodes (MELAS), US National Institute of Health; 2010. Available from: www.clinicaltrials.gov/ct2/show/NCT00887562?term=MElas&rank=2 [Last accessed 3 August 2010]
   Google Scholar
• Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet 2009;46:145-58
   PubMed Web of Science ®Google Scholar
• Carelli V, Barboni P, Zacchini A, Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci 1998;160:183-8
   PubMed Web of Science ®Google Scholar
• Cortelli P, Montagna P, Pierangeli G, Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci 1997;148:25-31
   PubMed Web of Science ®Google Scholar
• Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet 1992;340:368-9
   PubMed Web of Science ®Google Scholar
• Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol 2000;20:166-70
   PubMed Web of Science ®Google Scholar
• Barnils N, Mesa E, Munoz S, Response to idebenone and multivitamin therapy in Leber's hereditay optic neuropathy. Arch Soc Esp Oftalmol 2007;82:377-80
   PubMedGoogle Scholar
• Chinnery PF, Dimitriadis K, Rouleau J, Results of a 6-months randomized, placebo-controlled trial (RHODOS) with idebenone (Catena®) in Leber's Hereditary Optic Neuropathy (LHON). In 135th Annual Meeting of the American Neurological Association; 2010
   Google Scholar
• Bushby K, Finkel R, Birnkrant DJ, Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93
   PubMed Web of Science ®Google Scholar
• Buyse GM, Goemans N, Van der Mieren G, SNT-MC17/idebenone in Duchenne muscular dystrophy: long-term blinded controlled preclinical study in the mdx mouse followed by a 12 month double-blind randomized controlled trial in humans. Neuromusc Disord 2008;18:832
   Web of Science ®Google Scholar
• Buyse GM, Goemans N, van den Hauwe M, Glucocorticoids influence therapeutic efficacy of idebenone (Catena®) on peak expiratory flow in patients with Duchenne muscular dystrophy (DMD). Neuromusc Disord 2009;19:610
   Web of Science ®Google Scholar
• Buyse GM, Meier T, Finkel RS. Design of an international phase III study with idebenone (Catena®) in patients with Duchenne muscular dystrophy (DMD) – The DELOS study. Neuromusc Disord 2009;19:612
   Web of Science ®Google Scholar
• Miller DH, Siobhan ML. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903-12
   PubMed Web of Science ®Google Scholar
• Double blind placebo-controlled phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS), National Institute of Health. Available from: www.clinicaltrials.gov/ct2/show/NCT00950248?term=idebenone&rank=2 [Last accessed 24 March 2010]
   Google Scholar
• Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008;39:223-35
   PubMed Web of Science ®Google Scholar
• Haginoya K, Miyabayashi S, Kikuchi M, Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. J Neurol Sci 2009;278:112-14
   PubMed Web of Science ®Google Scholar
• Reddy PH, Mao P, Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev 2009;61:33-48
   PubMed Web of Science ®Google Scholar
• Ranen NG, Peyser CE, Coyle JT, A controlled trial of idebenone in Huntington's disease. Mov Disord 1996;11:549-54
   PubMed Web of Science ®Google Scholar
• Okamoto K, Matsumoto M, Watanabe M, Effects of 6-(omega-substituted alkyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinones and related compounds on mitochondrial succinate and reduced nicotinamide adenine dinucleotide oxidase systems. Chem Pharm Bull (Tokyo) 1985;33:3745-55
   PubMed Web of Science ®Google Scholar
• McGuffin M, Young AL. Premarket notifications of new dietary ingredients – a ten-year review. Food Drug Law J 2004;59:229-44
   PubMed Web of Science ®Google Scholar
• Torii H, Yoshida K, Kobayashi T, Disposition of idebenone (CV-2619), a new cerebral metabolism improving agent, in rats and dogs. J Pharmacobiodyn 1985;8:457-67
   PubMedGoogle Scholar
• Kobayashi T, Yoshida K, Mitani M, Metabolism of idebenone (CV-2619), a new cerebral metabolism improving agent: isolation and identification of metabolites in the rat and dog. J Pharmacobiodyn 1985;8:448-56
   PubMedGoogle Scholar
• Sugiyama Y, Fujita T, Matsumoto M, Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J Pharmacobiodyn 1985;8:1006-17
   PubMedGoogle Scholar
• Bodmer M, Vankan P, Dreier M, Pharmacokinetics and metabolism of idebenone in healthy male subjects. Eur J Clin Pharmacol 2009;65:493-501
   PubMed Web of Science ®Google Scholar
• Kutz K, Drewe J, Vankan P. Pharmacokinetic properties and metabolism of idebenone. J Neurol 2009;256(Suppl 1):31-5
   PubMedGoogle Scholar